Literature DB >> 6307099

Comparative effects of inhaled volcanic ash and quartz in rats.

T R Martin, E Y Chi, D S Covert, W A Hodson, D E Kessler, W E Moore, L C Altman, J Butler.   

Abstract

To investigate the relative toxicities of inhaled volcanic ash and quartz, we exposed matched groups of rats to either respirable volcanic ash (100 mg/m3), quartz (100 mg/m3), or clean air only for 6 h daily for 10 days. Thereafter, we examined animals sequentially for as long as 9 months, and measured changes in lung histopathologic aspects, air-space cells and lipids, and lung density. Neutron activation studies demonstrated that 3.3% of the inhaled daily dose of volcanic ash was detectable in the lung parenchyma. Volcanic ash was less toxic to the lung than quartz. Immediately after exposure, the lungs of animals treated with volcanic ash had ultrastructural evidence of damage to type I pneumocytes and early alveolar edema formation. By contrast, quartz-treated animals had an intense acute injury, with intraalveolar accumulation of lipid, protein, macrophages, and granulocytes. Six months after exposure, animals treated with volcanic ash had moderate interstitial thickening and fibrosis, whereas the quartz-treated animals had severe pulmonary fibrosis. Quartz, but not volcanic ash, caused a marked increase in lavage granulocytes, protein, and phospholipids. Lung density increased in quartz-exposed, but not in volcanic-ash-exposed animals. These data indicate that volcanic ash is less harmful to the lung parenchyma than is quartz. Persons exposed to volcanic ash for short periods are at much less risk of subsequent lung damage than are those who are exposed to similar amounts of quartz in the workplace.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307099     DOI: 10.1164/arrd.1983.128.1.144

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Short-term in vitro and in vivo bioassays: their role in estimating the toxic potential of inhaled complex mixtures for humans.

Authors:  J D Brain
Journal:  Cell Biol Toxicol       Date:  1992 Jul-Sep       Impact factor: 6.691

Review 2.  The role of surfactant in the pulmonary reaction to mineral particles.

Authors:  A G Heppleston
Journal:  Int J Exp Pathol       Date:  1991-10       Impact factor: 1.925

3.  Inflammation generating potential of long and short fibre amosite asbestos samples.

Authors:  K Donaldson; G M Brown; D M Brown; R E Bolton; J M Davis
Journal:  Br J Ind Med       Date:  1989-04

Review 4.  Evaluation of physical health effects due to volcanic hazards: the use of experimental systems to estimate the pulmonary toxicity of volcanic ash.

Authors:  T R Martin; A P Wehner; J Butler
Journal:  Am J Public Health       Date:  1986-03       Impact factor: 9.308

5.  The effect of products from bronchoalveolar-derived neutrophils on oxidant production and phagocytic activity of alveolar macrophages.

Authors:  K Donaldson; J Slight; R E Bolton
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

6.  Effect of aluminum inhalation on alveolar phospholipid profiles in experimental silicosis.

Authors:  R Bégin; F Possmayer; M A Ormseth; M Martel; A Cantin; S Massé
Journal:  Lung       Date:  1989       Impact factor: 2.584

7.  Persistent biological reactivity of quartz in the lung: raised protease burden compared with a non-pathogenic mineral dust and microbial particles.

Authors:  G M Brown; D M Brown; J Slight; K Donaldson
Journal:  Br J Ind Med       Date:  1991-01

8.  The structure of volcanic cristobalite in relation to its toxicity; relevance for the variable crystalline silica hazard.

Authors:  Claire J Horwell; Benedict J Williamson; Ken Donaldson; Jennifer S Le Blond; David E Damby; Leon Bowen
Journal:  Part Fibre Toxicol       Date:  2012-11-19       Impact factor: 9.400

9.  Recovery of rat alveolar macrophages by bronchoalveolar lavage under normal and activated conditions.

Authors:  B Rehn; J Bruch; T Zou; G Hobusch
Journal:  Environ Health Perspect       Date:  1992-07       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.